Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
CrossRef.
Thoma, Achilleas
Kaur, Manraj Nirmal
Tsoi, Bernice
Ziolkowski, Natalia
Duku, Eric
and
Goldsmith, Charles Harry
2014.
Cost-Effectiveness Analysis Parallel to a Randomized Controlled Trial Comparing Vertical Scar Reduction and Inverted T–Shaped Reduction Mammaplasty.
Plastic and Reconstructive Surgery,
Vol. 134,
Issue. 6,
p.
1093.
Cronin, Paul
Rawson, James V.
Heilbrun, Marta E.
Lee, Janie M.
Kelly, Aine M.
Sanelli, Pina C.
Bresnahan, Brian W.
and
Paladin, Angelisa M.
2014.
How to Report a Research Study.
Academic Radiology,
Vol. 21,
Issue. 9,
p.
1088.
Barocas, Daniel A.
Bensink, Mark E.
Berry, Kristin
Musa, Zahra
Bodnar, Carolyn
Dann, Robert
and
Ramsey, Scott D.
2014.
ECONOMIC EVALUATION OF DIAGNOSTIC LOCALIZATION FOLLOWING BIOCHEMICAL PROSTATE CANCER RECURRENCE.
International Journal of Technology Assessment in Health Care,
Vol. 30,
Issue. 4,
p.
345.
Rosén, Måns
2014.
WHO SHOULD CONDUCT MODELING AND COST-EFFECTIVENESS ANALYSIS?.
International Journal of Technology Assessment in Health Care,
Vol. 30,
Issue. 1,
p.
128.
Marchetti, Monia
and
Liberato, Nicola Lucio
2014.
Biological therapies in Crohn’s disease: are they cost-effective? A critical appraisal of model-based analyses.
Expert Review of Pharmacoeconomics & Outcomes Research,
Vol. 14,
Issue. 6,
p.
815.
Cronin, Paul
Rawson, James V.
Heilbrun, Marta E.
Lee, Janie M.
Kelly, Aine M.
Sanelli, Pina C.
Bresnahan, Brian W.
and
Paladin, Angelisa M.
2014.
How to Critically Appraise the Clinical Literature.
Academic Radiology,
Vol. 21,
Issue. 9,
p.
1117.
Davis, Jennifer C
Verhagen, Evert
Bryan, Stirling
Liu-Ambrose, Teresa
Borland, Jeff
Buchner, David
Hendriks, Marike RC
Weiler, Richard
Morrow, James R
van Mechelen, Willem
Blair, Steven N
Pratt, Mike
Windt, Johann
al-Tunaiji, Hashel
Macri, Erin
and
Khan, Karim M
2014.
2014 Consensus Statement from the first Economics of Physical Inactivity Consensus (EPIC) Conference (Vancouver).
British Journal of Sports Medicine,
Vol. 48,
Issue. 12,
p.
947.
Husereau, Don
Marshall, Deborah A.
Levy, Adrian R.
Peacock, Stuart
and
Hoch, Jeffrey S.
2014.
HEALTH TECHNOLOGY ASSESSMENT AND PERSONALIZED MEDICINE: ARE ECONOMIC EVALUATION GUIDELINES SUFFICIENT TO SUPPORT DECISION MAKING?.
International Journal of Technology Assessment in Health Care,
Vol. 30,
Issue. 2,
p.
179.
Frappier, Julie
Tremblay, Gabriel
Charny, Mark
and
Cloutier, L. Martin
2015.
Costing bias in economic evaluations.
Journal of Medical Economics,
Vol. 18,
Issue. 8,
p.
596.
Peters, J. L.
Cooper, C.
and
Buchanan, J.
2015.
Evidence used in model-based economic evaluations for evaluating pharmacogenetic and pharmacogenomic tests: a systematic review protocol.
BMJ Open,
Vol. 5,
Issue. 11,
p.
e008465.
Walker, Graham
Alexandrou, Evan
Rickard, Claire M
Chan, Raymond J
and
Webster, Joan
2015.
Effectiveness of electrocardiographic guidance in CVAD tip placement.
British Journal of Nursing,
Vol. 24,
Issue. Sup14,
p.
S4.
Setiawan, Didik
Luttjeboer, Jos
Westra, Tjalke Arend
Wilschut, Jan C
Suwantika, Auliya A
Daemen, Toos
Atthobari, Jarir
Wilffert, Bob
and
Postma, Maarten J
2015.
The cost–effectiveness of HPV vaccination in addition to screening: a Dutch perspective.
Expert Review of Vaccines,
Vol. 14,
Issue. 4,
p.
589.
Freeman, Karoline
Connock, Martin
Cummins, Ewen
Gurung, Tara
Taylor-Phillips, Sian
Court, Rachel
Saunders, Mark
Clarke, Aileen
and
Sutcliffe, Paul
2015.
Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion.
Health Technology Assessment,
Vol. 19,
Issue. 91,
p.
1.
Sailer, Anna M.
van Zwam, Wim H.
Wildberger, Joachim E.
and
Grutters, Janneke P. C.
2015.
Cost-effectiveness modelling in diagnostic imaging: a stepwise approach.
European Radiology,
Vol. 25,
Issue. 12,
p.
3629.
Pérez, Antonio
Mezquita Raya, Pedro
Ramírez de Arellano, Antonio
Briones, Teresa
Hunt, Barnaby
and
Valentine, William J.
2015.
Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin.
Diabetes Therapy,
Vol. 6,
Issue. 1,
p.
61.
Dukhovny, Dmitry
Pursley, DeWayne M.
Kirpalani, Haresh M.
Horbar, Jeffrey H.
and
Zupancic, John A. F.
2016.
Evidence, Quality, and Waste: Solving the Value Equation in Neonatology.
Pediatrics,
Vol. 137,
Issue. 3,
de Boer, Pieter T.
Frederix, Geert W. J.
Feenstra, Talitha L.
and
Vemer, Pepijn
2016.
Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer.
PharmacoEconomics,
Vol. 34,
Issue. 9,
p.
833.
Gallagher, James
O’Sullivan, David
McCarthy, Suzanne
Gillespie, Paddy
Woods, Noel
O’Mahony, Denis
and
Byrne, Stephen
2016.
Structured Pharmacist Review of Medication in Older Hospitalised Patients: A Cost-Effectiveness Analysis.
Drugs & Aging,
Vol. 33,
Issue. 4,
p.
285.
Cronin, Paul
and
Rawson, James V.
2016.
Review of Research Reporting Guidelines for Radiology Researchers.
Academic Radiology,
Vol. 23,
Issue. 5,
p.
537.
Roussel, Ronan
Martinez, Luc
Vandebrouck, Tom
Douik, Habiba
Emiel, Patrick
Guery, Matthieu
Hunt, Barnaby
and
Valentine, William J.
2016.
Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France.
Journal of Medical Economics,
Vol. 19,
Issue. 2,
p.
131.